Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 44(5): 532-8, 2015 09.
Artículo en Chino | MEDLINE | ID: mdl-26713528

RESUMEN

OBJECTIVE: To investigate the effects of ulinastatin(UTI) on postoperative cognitive function in patients undergoing coronary artery bypass grafting. METHODS: One hundred and twenty-seven patients undergoing elective coronary artery bypass surgery were randomly divided into three groups:high-dose UTI group(16000 U/kg i.v.), low-dose UTI group(8000 U/kg i.v.) and control group(normal saline). The levels of plasma cortisol were measured before and one day after surgery. The level of IL-6, IL-10, TNF-α and S100ß were measured before operation(T0), at open chest(T1), end of operation(T2), 6 h(T3)and 24 h(T4) after operation. A neuropsychological test scale was to evaluate the cognitive function 1 day before operation, 1 week and 3 months after operation. RESULTS: Ninety-three patients completed the study. There was no significant difference in general information of patients among three groups(P>0.05). The level of plasma cortisol one day after operation was significantly higher than that before operation in control group(P<0.01). The levels of plasma cortisol in high-dose UTI group and low-dose UTI group were lower than that of control group(P<0.01). In all groups, the level of plasma IL-6, IL-10, TNF-α and S100B increased remarkably at T2, T3, T4 compared to those at T0(all P<0.05). The level of plasma IL-6, TNF-α(at T2, T3, T4)and S100ß(at T3)in high-dose UTI group and low-dose UTI group were all lower than those of control group(P<0.05),while there were no significant differences between high-dose UTI group and low-dose UTI group(P>0.05). The incidence of postoperative cognitive dysfunction in POCD 1 week after operation in high-dose UTI and low-dose UTI groups(25.8% and 23.3%)was lower than that in control group(50.0%), while there were no significant difference 1 month after operation between high-dose UTI group(12.9%) or low-dose UTI group(16.7%)and control group(28.1%). The level of plasma S100ß at T2 of POCD patients(n=31)was higher than that of non-POCD group(n=62)(P<0.05). CONCLUSION: Ulinastatin can reduce the incidence of postoperative cognitive dusfunction 1 week after coronary artery bypass surgery, which might be associated with inhibition of inflammation and S100ß expression.


Asunto(s)
Cognición/efectos de los fármacos , Puente de Arteria Coronaria , Glicoproteínas/uso terapéutico , Humanos , Inflamación/tratamiento farmacológico , Interleucina-10/sangre , Interleucina-6/sangre , Complicaciones Posoperatorias/prevención & control , Subunidad beta de la Proteína de Unión al Calcio S100/sangre , Factor de Necrosis Tumoral alfa/sangre
2.
Mol Cell Endocrinol ; 362(1-2): 128-38, 2012 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-22698522

RESUMEN

The aim of the present study was to determine the effect of baicalein on metabolic syndrome induced by a high-fat diet in mice. The mice developed obesity, dyslipidemia, fatty liver, diabetes and insulin resistance. These disorders were effectively normalized in baicalein-treated mice. Further investigation revealed that the inhibitory effect on inflammation and insulin resistance was mediated by inhibition of the MAPKs pathway and activation of the IRS1/PI3K/Akt pathway. The lipid-lowering effect was attributed to the blocking of synthesis way mediated by SERBP-1c, PPARγ and the increased fatty acid oxidation. All of these effects depended on AMPKα activation. These results were confirmed in the primary hepatocytes from wild type and AMPKα(2)(-/-) mice. However, the IRS-1/PI3K/AKT pathway showed no change, which may be due to the time of stimulation and concentration. Thus, these data suggested that baicalein protects mice from metabolic syndrome through an AMPKα(2)-dependent mechanism involving multiple intracellular signaling pathways.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Dieta Alta en Grasa/efectos adversos , Medicamentos Herbarios Chinos/farmacología , Activadores de Enzimas/farmacología , Flavanonas/farmacología , Síndrome Metabólico/tratamiento farmacológico , Animales , Vías Biosintéticas/genética , Glucemia , Peso Corporal/efectos de los fármacos , Células Cultivadas , Quimiocina CCL2/sangre , Medicamentos Herbarios Chinos/uso terapéutico , Metabolismo Energético , Activadores de Enzimas/uso terapéutico , Ácidos Grasos/biosíntesis , Hígado Graso/tratamiento farmacológico , Hígado Graso/etiología , Hígado Graso/patología , Flavanonas/uso terapéutico , Expresión Génica/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Resistencia a la Insulina , Sistema de Señalización de MAP Quinasas , Masculino , Síndrome Metabólico/enzimología , Síndrome Metabólico/etiología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Obesidad Abdominal/tratamiento farmacológico , Obesidad Abdominal/enzimología , Obesidad Abdominal/etiología , Estrés Oxidativo , Factor de Necrosis Tumoral alfa/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA